These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 17383431)

  • 1. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
    Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF
    Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
    Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Gradilone SA; Huang B; Masyuk AI; Hogan MC; Torres VE; Larusso NF
    Hepatology; 2013 Jul; 58(1):409-21. PubMed ID: 23172758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD).
    Banales JM; Masyuk TV; Gradilone SA; Masyuk AI; Medina JF; LaRusso NF
    Hepatology; 2009 Jan; 49(1):160-74. PubMed ID: 19065671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
    Masyuk TV; Masyuk AI; Lorenzo Pisarello M; Howard BN; Huang BQ; Lee PY; Fung X; Sergienko E; Ardecky RJ; Chung TDY; Pinkerton AB; LaRusso NF
    Hepatology; 2017 Oct; 66(4):1197-1218. PubMed ID: 28543567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.
    Banales JM; Masyuk TV; Bogert PS; Huang BQ; Gradilone SA; Lee SO; Stroope AJ; Masyuk AI; Medina JF; LaRusso NF
    Am J Pathol; 2008 Dec; 173(6):1637-46. PubMed ID: 18988797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
    Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
    Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
    Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
    Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
    Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
    J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.
    Gradilone SA; Masyuk TV; Huang BQ; Banales JM; Lehmann GL; Radtke BN; Stroope A; Masyuk AI; Splinter PL; LaRusso NF
    Gastroenterology; 2010 Jul; 139(1):304-14.e2. PubMed ID: 20399209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.
    Urribarri AD; Munoz-Garrido P; Perugorria MJ; Erice O; Merino-Azpitarte M; Arbelaiz A; Lozano E; Hijona E; Jiménez-Agüero R; Fernandez-Barrena MG; Jimeno JP; Marzioni M; Marin JJ; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Banales JM
    Gut; 2014 Oct; 63(10):1658-67. PubMed ID: 24436140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease.
    Lee SO; Masyuk T; Splinter P; Banales JM; Masyuk A; Stroope A; Larusso N
    J Clin Invest; 2008 Nov; 118(11):3714-24. PubMed ID: 18949056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease.
    Kugita M; Nishii K; Yamaguchi T; Suzuki A; Yuzawa Y; Horie S; Higashihara E; Nagao S
    PLoS One; 2017; 12(5):e0177934. PubMed ID: 28542433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
    Yoshihara D; Kugita M; Sasaki M; Horie S; Nakanishi K; Abe T; Aukema HM; Yamaguchi T; Nagao S
    PLoS One; 2013; 8(12):e81480. PubMed ID: 24324698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
    Masyuk AI; Masyuk TV; Lorenzo Pisarello MJ; Ding JF; Loarca L; Huang BQ; LaRusso NF
    Hepatology; 2018 Mar; 67(3):1088-1108. PubMed ID: 29023824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feeding soy protein isolate and n-3 PUFA affects polycystic liver disease progression in a PCK rat model of autosomal polycystic kidney disease.
    Maditz KH; Benedito VA; Oldaker C; Nanda N; Lateef SS; Livengood R; Tou JC
    J Pediatr Gastroenterol Nutr; 2015 Apr; 60(4):467-73. PubMed ID: 25822773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of a cholangiocyte cell line from the PCK rat, an animal model of Autosomal Recessive Polycystic Kidney Disease.
    Muff MA; Masyuk TV; Stroope AJ; Huang BQ; Splinter PL; Lee SO; Larusso NF
    Lab Invest; 2006 Sep; 86(9):940-50. PubMed ID: 16783394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat.
    Masyuk TV; Huang BQ; Ward CJ; Masyuk AI; Yuan D; Splinter PL; Punyashthiti R; Ritman EL; Torres VE; Harris PC; LaRusso NF
    Gastroenterology; 2003 Nov; 125(5):1303-10. PubMed ID: 14598246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.
    Wang X; Harris PC; Somlo S; Batlle D; Torres VE
    Nephrol Dial Transplant; 2009 Feb; 24(2):526-34. PubMed ID: 18826972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Mast Cell Degranulation With Cromolyn Sodium Exhibits Organ-Specific Effects in Polycystic Kidney (PCK) Rats.
    Jiang L; Fang P; Septer S; Apte U; Pritchard MT
    Int J Toxicol; 2018; 37(4):308-326. PubMed ID: 29862868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
    Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
    JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.